Summary
Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2016’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)
- The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects
- The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AbbVie Inc.
AbGenomics International, Inc.
Actelion Ltd
Alexion Pharmaceuticals, Inc.
Apceth GmbH & Co. KG
arGEN-X BV
Athersys, Inc.
Bellicum Pharmaceuticals, Inc.
Bio-Cancer Treatment International Limited
Biogen, Inc.
Bristol-Myers Squibb Company
Caladrius Biosciences, Inc.
Cantex Pharmaceuticals, Inc.
Cell2B S.A.
CellECT Bio, Inc.
Cynata Therapeutics Limited
Cytodyn Inc.
Dr. Falk Pharma GmbH
Effimune SAS
Escape Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Fate Therapeutics, Inc.
Generon (Shanghai) Corporation Ltd.
GlaxoSmithKline Plc
Idera Pharmaceuticals, Inc.
ImmuNext, Inc.
Immunomedics, Inc.
Incyte Corporation
Kadmon Corporation, LLC
Kamada Ltd.
Kiadis Pharma B.V.
Kymab Limited
Kyorin Pharmaceutical Co., Ltd.
MacroGenics, Inc.
Mallinckrodt Plc
Medsenic
Mesoblast Limited
Millennium Pharmaceuticals, Inc.
Neopharm Ltd.
Novartis AG
OncoImmune, Inc.
Pharmicell Co., Ltd.
REGiMMUNE Corporation
Rigel Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Seattle Genetics, Inc.
Seres Therapeutics, Inc.
Sigmoid Pharma Limited
Spherium Biomed S.L.
Targazyme, Inc.
Therapix Biosciences Ltd
Tobira Therapeutics, Inc.
Xenikos B.V.
ZIOPHARM Oncology, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Graft Versus Host Disease (GVHD) Overview 11
Therapeutics Development 12
Pipeline Products for Graft Versus Host Disease (GVHD) - Overview 12
Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis 13
Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies 14
Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes 18
Graft Versus Host Disease (GVHD) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Graft Versus Host Disease (GVHD) - Products under Development by Companies 23
Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes 27
Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development 28
AbbVie Inc. 28
AbGenomics International, Inc. 29
Actelion Ltd 30
Alexion Pharmaceuticals, Inc. 31
Apceth GmbH & Co. KG 32
arGEN-X BV 33
Athersys, Inc. 34
Bellicum Pharmaceuticals, Inc. 35
Bio-Cancer Treatment International Limited 36
Biogen, Inc. 37
Bristol-Myers Squibb Company 38
Caladrius Biosciences, Inc. 39
Cantex Pharmaceuticals, Inc. 40
Cell2B S.A. 41
CellECT Bio, Inc. 42
Cynata Therapeutics Limited 43
Cytodyn Inc. 44
Dr. Falk Pharma GmbH 45
Effimune SAS 46
Escape Therapeutics, Inc. 47
F. Hoffmann-La Roche Ltd. 48
Fate Therapeutics, Inc. 49
Generon (Shanghai) Corporation Ltd. 50
GlaxoSmithKline Plc 51
Idera Pharmaceuticals, Inc. 52
ImmuNext, Inc. 53
Immunomedics, Inc. 54
Incyte Corporation 55
Kadmon Corporation, LLC 56
Kamada Ltd. 57
Kiadis Pharma B.V. 58
Kymab Limited 59
Kyorin Pharmaceutical Co., Ltd. 60
MacroGenics, Inc. 61
Mallinckrodt Plc 62
Medsenic 63
Mesoblast Limited 64
Millennium Pharmaceuticals, Inc. 65
Neopharm Ltd. 66
Novartis AG 67
OncoImmune, Inc. 68
Pharmicell Co., Ltd. 69
REGiMMUNE Corporation 70
Rigel Pharmaceuticals, Inc. 71
Sarepta Therapeutics, Inc. 72
Seattle Genetics, Inc. 73
Seres Therapeutics, Inc. 74
Sigmoid Pharma Limited 75
Spherium Biomed S.L. 76
Targazyme, Inc. 77
Therapix Biosciences Ltd 78
Tobira Therapeutics, Inc. 79
Xenikos B.V. 80
ZIOPHARM Oncology, Inc. 81
Graft Versus Host Disease (GVHD) - Therapeutics Assessment 82
Assessment by Monotherapy Products 82
Assessment by Combination Products 83
Assessment by Target 84
Assessment by Mechanism of Action 88
Assessment by Route of Administration 91
Assessment by Molecule Type 93
Drug Profiles 95
abatacept - Drug Profile 95
AbGn-168H - Drug Profile 98
aldesleukin - Drug Profile 99
Alecmestencel-L - Drug Profile 101
alpha-1 proteinase inhibitor (human) - Drug Profile 102
ALXN-1007 - Drug Profile 104
anti-thymocyte globulin (rabbit) - Drug Profile 105
Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 107
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 108
ARGX-115 - Drug Profile 109
arsenic trioxide - Drug Profile 110
ATIR-101 - Drug Profile 111
BCT-200 - Drug Profile 113
begelomab - Drug Profile 114
Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 115
Biologics for Graft Versus Host Disease - Drug Profile 116
bortezomib - Drug Profile 117
BPX-501 - Drug Profile 123
brentuximab vedotin - Drug Profile 125
budesonide - Drug Profile 132
cannabidiol - Drug Profile 135
CD-24Fc - Drug Profile 137
Cellgram for Graft Versus Host Disease - Drug Profile 138
Cellular Immunotherapy for Autoimmune Diseases and GVHD - Drug Profile 139
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 141
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 142
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 143
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 144
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 145
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 146
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 147
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 148
Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile 149
cenicriviroc mesylate - Drug Profile 150
CLBS-03 - Drug Profile 152
CRCBT-080004 - Drug Profile 153
CX-01 - Drug Profile 154
cyclosporine CR + cyclosporine IR - Drug Profile 156
CYP-001 - Drug Profile 157
F-652 - Drug Profile 158
FR-104 - Drug Profile 159
Ha-7 - Drug Profile 161
ibrutinib - Drug Profile 162
ImmuneSafe - Drug Profile 170
IMO-8400 - Drug Profile 172
IT-603 - Drug Profile 174
IT-901 - Drug Profile 175
itacitinib adipate - Drug Profile 176
KD-025 - Drug Profile 178
KRP-203 - Drug Profile 180
KY-1005 - Drug Profile 182
MAX-16H5 - Drug Profile 183
MesoStem - Drug Profile 184
methoxsalen - Drug Profile 185
MGD-010 - Drug Profile 187
milatuzumab - Drug Profile 189
Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile 191
natalizumab - Drug Profile 193
OCU-300 - Drug Profile 195
Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 196
panobinostat - Drug Profile 197
PF-05285401 - Drug Profile 204
ponesimod - Drug Profile 209
Preimplantation Factor - Drug Profile 211
PRO-140 - Drug Profile 213
ProTmune - Drug Profile 218
Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders - Drug Profile 219
Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile 220
Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile 221
remestemcel-L - Drug Profile 222
RGI-2001 - Drug Profile 226
RO-2959 - Drug Profile 228
SER-155 - Drug Profile 229
Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders - Drug Profile 230
Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorders - Drug Profile 231
Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile 232
Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 233
sonidegib phosphate - Drug Profile 234
SP-12008 - Drug Profile 238
Substance X - Drug Profile 239
SYGN-305G - Drug Profile 240
T-Guard - Drug Profile 241
TZ-101 - Drug Profile 243
ZL-1101 - Drug Profile 245
Graft Versus Host Disease (GVHD) - Recent Pipeline Updates 246
Graft Versus Host Disease (GVHD) - Dormant Projects 347
Graft Versus Host Disease (GVHD) - Discontinued Products 352
Graft Versus Host Disease (GVHD) - Product Development Milestones 353
Featured News & Press Releases 353
Appendix 360
Methodology 360
Coverage 360
Secondary Research 360
Primary Research 360
Expert Panel Validation 360
Contact Us 360
Disclaimer 361
List of Tables
Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2016 18
Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H1 2016 19
Number of Products under Development by Companies, H1 2016 20
Number of Products under Development by Companies, H1 2016 (Contd..1) 21
Number of Products under Development by Companies, H1 2016 (Contd..2) 22
Number of Products under Development by Companies, H1 2016 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2016 24
Comparative Analysis by Late Stage Development, H1 2016 25
Comparative Analysis by Clinical Stage Development, H1 2016 26
Comparative Analysis by Early Stage Development, H1 2016 27
Comparative Analysis by Unknown Stage Development, H1 2016 28
Products under Development by Companies, H1 2016 29
Products under Development by Companies, H1 2016 (Contd..1) 30
Products under Development by Companies, H1 2016 (Contd..2) 31
Products under Development by Companies, H1 2016 (Contd..3) 32
Products under Investigation by Universities/Institutes, H1 2016 33
Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc., H1 2016 34
Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H1 2016 35
Graft Versus Host Disease (GVHD) - Pipeline by Actelion Ltd, H1 2016 36
Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 37
Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H1 2016 38
Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H1 2016 39
Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H1 2016 40
Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 41
Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 42
Graft Versus Host Disease (GVHD) - Pipeline by Biogen, Inc., H1 2016 43
Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H1 2016 44
Graft Versus Host Disease (GVHD) - Pipeline by Caladrius Biosciences, Inc. , H1 2016 45
Graft Versus Host Disease (GVHD) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 46
Graft Versus Host Disease (GVHD) - Pipeline by Cell2B S.A. , H1 2016 47
Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio, Inc., H1 2016 48
Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Limited, H1 2016 49
Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc., H1 2016 50
Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H1 2016 51
Graft Versus Host Disease (GVHD) - Pipeline by Effimune SAS, H1 2016 52
Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H1 2016 53
Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 54
Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics, Inc., H1 2016 55
Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2016 56
Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H1 2016 57
Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 58
Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H1 2016 59
Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H1 2016 60
Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corporation, H1 2016 61
Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H1 2016 62
Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H1 2016 63
Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma B.V., H1 2016 64
Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H1 2016 65
Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 66
Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics, Inc., H1 2016 67
Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, H1 2016 68
Graft Versus Host Disease (GVHD) - Pipeline by Medsenic, H1 2016 69
Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H1 2016 70
Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 71
Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H1 2016 72
Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H1 2016 73
Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune, Inc., H1 2016 74
Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H1 2016 75
Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H1 2016 76
Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2016 77
Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H1 2016 78
Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H1 2016 79
Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics, Inc., H1 2016 80
Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H1 2016 81
Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H1 2016 82
Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H1 2016 83
Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd, H1 2016 84
Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H1 2016 85
Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H1 2016 86
Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology, Inc., H1 2016 87
Assessment by Monotherapy Products, H1 2016 88
Assessment by Combination Products, H1 2016 89
Number of Products by Stage and Target, H1 2016 91
Number of Products by Stage and Mechanism of Action, H1 2016 95
Number of Products by Stage and Route of Administration, H1 2016 98
Number of Products by Stage and Molecule Type, H1 2016 100
Graft Versus Host Disease (GVHD) Therapeutics - Recent Pipeline Updates, H1 2016 252
Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2016 353
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H1 2016 354
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H1 2016 355
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H1 2016 356
Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..4), H1 2016 357
Graft Versus Host Disease (GVHD) - Discontinued Products, H1 2016 358
List of Figures
Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2016 18
Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H1 2016 19
Number of Products under Development by Companies, H1 2016 20
Number of Products under Investigation by Universities/Institutes, H1 2016 24
Comparative Analysis by Clinical Stage Development, H1 2016 26
Comparative Analysis by Early Stage Products, H1 2016 27
Assessment by Monotherapy Products, H1 2016 88
Number of Products by Top 10 Targets, H1 2016 90
Number of Products by Stage and Top 10 Targets, H1 2016 90
Number of Products by Top 10 Mechanism of Actions, H1 2016 94
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 94
Number of Products by Routes of Administration, H1 2016 97
Number of Products by Stage and Routes of Administration, H1 2016 97
Number of Products by Molecule Types, H1 2016 99
Number of Products by Stage and Molecule Types, H1 2016 99
